Literature DB >> 24685638

Dopamine D(3) receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia.

Michelle G Baladi1, Amy H Newman2, Shannon M Nielsen1, Glen R Hanson3, Annette E Fleckenstein4.   

Abstract

Methamphetamine administration causes long-term deficits to dopaminergic systems that, in humans, are thought to be associated with motor slowing and memory impairment. Methamphetamine interacts with the dopamine transporter (DAT) and increases extracellular concentrations of dopamine that, in turn, binds to a number of dopamine receptor subtypes. Although the relative contribution of each receptor subtype to the effects of methamphetamine is not fully known, non-selective dopamine D2/D3 receptor antagonists can attenuate methamphetamine-induced changes to dopamine systems. The present study extended these findings by testing the role of the dopamine D3 receptor subtype in mediating the long-term dopaminergic, and for comparison serotonergic, deficits caused by methamphetamine. Results indicate that the dopamine D3 receptor selective antagonist, PG01037, attenuated methamphetamine-induced decreases in striatal DAT, but not hippocampal serotonin (5HT) transporter (SERT), function, as assessed 7 days after treatment. However, PG01037 also attenuated methamphetamine-induced hyperthermia. When methamphetamine-induced hyperthermia was maintained by treating rats in a warm ambient environment, PG01037 failed to attenuate the effects of methamphetamine on DAT uptake. Furthermore, PG01037 did not attenuate methamphetamine-induced decreases in dopamine and 5HT content. Taken together, the present study demonstrates that dopamine D3 receptors mediate, in part, the long-term deficits in DAT function caused by methamphetamine, and that this effect likely involves an attenuation of methamphetamine-induced hyperthermia.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  D(3) antagonist; Dopamine D(3) receptors; Dopamine transporter; Methamphetamine; PG01037; Serotonin transporter

Mesh:

Substances:

Year:  2014        PMID: 24685638      PMCID: PMC4060957          DOI: 10.1016/j.ejphar.2014.03.023

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  51 in total

1.  Striatal and cortical NMDA receptors are altered by a neurotoxic regimen of methamphetamine.

Authors:  A J Eisch; S J O'Dell; J F Marshall
Journal:  Synapse       Date:  1996-03       Impact factor: 2.562

2.  4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse.

Authors:  Gregory C Hadlock; Katy M Webb; Lisa M McFadden; Pei Wen Chu; Jonathan D Ellis; Scott C Allen; David M Andrenyak; Paula L Vieira-Brock; Christopher L German; Kevin M Conrad; Amanda J Hoonakker; James W Gibb; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2011-08-02       Impact factor: 4.030

3.  Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.

Authors:  Lisa M McFadden; Greg C Hadlock; Scott C Allen; Paula L Vieira-Brock; Kristen A Stout; Jonathan D Ellis; Amanda J Hoonakker; David M Andrenyak; Shannon M Nielsen; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2011-10-27       Impact factor: 4.030

4.  Methamphetamine neurotoxicity decreases phasic, but not tonic, dopaminergic signaling in the rat striatum.

Authors:  Christopher D Howard; Kristen A Keefe; Paul A Garris; David P Daberkow
Journal:  J Neurochem       Date:  2011-07-01       Impact factor: 5.372

5.  Eating high-fat chow enhances sensitization to the effects of methamphetamine on locomotion in rats.

Authors:  Blaine A McGuire; Michelle G Baladi; Charles P France
Journal:  Eur J Pharmacol       Date:  2011-03-01       Impact factor: 4.432

6.  Striatal dopamine D1 and D2 receptors: widespread influences on methamphetamine-induced dopamine and serotonin neurotoxicity.

Authors:  Noah B Gross; Patrick C Duncker; John F Marshall
Journal:  Synapse       Date:  2011-08-31       Impact factor: 2.562

7.  Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA.

Authors:  Noelia Granado; Sara Ares-Santos; Idaira Oliva; Esther O'Shea; Eduardo D Martin; M Isabel Colado; Rosario Moratalla
Journal:  Neurobiol Dis       Date:  2011-02-15       Impact factor: 5.996

8.  Striatal dopamine nerve terminal markers in human, chronic methamphetamine users.

Authors:  J M Wilson; K S Kalasinsky; A I Levey; C Bergeron; G Reiber; R M Anthony; G A Schmunk; K Shannak; J W Haycock; S J Kish
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

9.  Role of hypothermia in the mechanism of protection against serotonergic toxicity. II. Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan.

Authors:  G M Farfel; L S Seiden
Journal:  J Pharmacol Exp Ther       Date:  1995-02       Impact factor: 4.030

10.  Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine.

Authors:  R Kuczenski; D S Segal; A K Cho; W Melega
Journal:  J Neurosci       Date:  1995-02       Impact factor: 6.167

View more
  7 in total

Review 1.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

2.  Heightened Dopaminergic Response to Amphetamine at the D3 Dopamine Receptor in Methamphetamine Users.

Authors:  Isabelle Boileau; Doris Payer; Pablo M Rusjan; Sylvain Houle; Junchao Tong; Tina McCluskey; Alan A Wilson; Stephen J Kish
Journal:  Neuropsychopharmacology       Date:  2016-06-29       Impact factor: 7.853

Review 3.  Chronic methamphetamine abuse and corticostriatal deficits revealed by neuroimaging.

Authors:  Edythe D London; Milky Kohno; Angelica M Morales; Michael E Ballard
Journal:  Brain Res       Date:  2014-11-04       Impact factor: 3.252

Review 4.  Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology.

Authors:  Shaobin Yu; Ling Zhu; Qiang Shen; Xue Bai; Xuhui Di
Journal:  Behav Neurol       Date:  2015-03-12       Impact factor: 3.342

Review 5.  Dopamine compartmentalization, selective dopaminergic vulnerabilities in Parkinson's disease and therapeutic opportunities.

Authors:  George R Uhl
Journal:  Ann Clin Transl Neurol       Date:  2019-01-08       Impact factor: 4.511

6.  Enhanced Dopamine Transmission and Hyperactivity in the Dopamine Transporter Heterozygous Mice Lacking the D3 Dopamine Receptor.

Authors:  Tatyana D Sotnikova; Evgeniya V Efimova; Raul R Gainetdinov
Journal:  Int J Mol Sci       Date:  2020-11-03       Impact factor: 5.923

7.  The Role of Hyperthermia in Methamphetamine-Induced Depression-Like Behaviors: Protective Effects of Coral Calcium Hydride.

Authors:  Xintao Wang; Bonan Tong; Rongji Hui; Congcong Hou; Zilu Zhang; Ludi Zhang; Bing Xie; Zhiyu Ni; Bin Cong; Chunling Ma; Di Wen
Journal:  Front Mol Neurosci       Date:  2022-01-04       Impact factor: 5.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.